Dolat Capital: Laurus Labs Adds Capabilities In Biotech
The antiviral medication being manufactured in Russia. (Photographer Andrey Rudakov/Bloomberg)

Dolat Capital: Laurus Labs Adds Capabilities In Biotech

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

Laurus Labs Ltd. acquired 72.5% stake in Richcore Lifesciences Pvt Ltd. for Rs 2.5 billion funded through internal accruals.

The company will be acquiring existing shareholding of PE funds Eight Road Ventures and Ventur East, while the existing founder and promoter will continue to run the operations.

The transaction will be completed in approximately three months. The acquisition is over and above the Rs 12 billion capex program.

Click on the attachment to read the full report:

Dolat Capital Laurus Labs Event Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.